A study that reveals the benefits of "turlonomic" in the delay of the symptoms of "multiple sclerosis"

A preliminary scientific study, the results of which were published at the annual American Academy meeting, revealed that the drug “turlonomic” shows the rise of early symptoms of people who show signs of “multiple sclerosis” in the MRI examination, although the symptoms of the disease do not appear on them. This condition is diagnosed in people who do not suffer from symptoms of multiple sclerosis, but they have deformations of brain or spinal cord, called pests, and are similar to those found in the disease. Multiple nerve sclerosis is a disease in which the immune system in the body is attacked by Myelin, which is the white fatty substance that isolate and protect the nerves. The disease contains symptoms such as fatigue, numbness, tingling and problems with the barrel. “Treflunumide” works by impeding an enzyme involved in the synthesis of DNA in immune cells. Preventing this enzyme helps the drug to reduce the activity of the immune system, which can prevent nerve damage, and the slower progress of multiple sclerosis. The medicine is taken orally in the form of pills, usually once a day. Common side effects of this medicine include nausea, diarrhea, hair loss and height of liver enzymes. The treatment of auto -immune diseases This drug was first discovered in the 1990s, as part of a research program aimed at developing new treatments for auto -immune diseases. The boat was originally discovered as a candidate for the treatment of infections, and other studies have shown that it has immune properties that can be effective in treating multiple sclerosis. The clinical trials of the therapeutic use of the drug began in multiple and twenty -century in multiple sclerosis, and in 2012 the American food and medicine application agreed to use the drug to treat troublesome forms of multiple sclerosis. Since then, other countries have followed the same steps to agree to use the drug, and have now become a record choice in the treatment of these cases. This is the first time the ability of the drug has delayed the rise of early symptoms of multiple sclerosis in patients who did not look symptoms. The drug manufacturer supported this new study. The average monthly dose price of the drug “$ 14 milligrams” is about $ 3300 in the United States. “The more patients with multiple sclerosis are treated quickly, the greater the chances of delaying miles of damage, reducing the risk of permanent nervous weakness and exhausted symptoms,” says Dr. Christine Leberron Fernee, a colleague of the American Academy of Neurology and the first author of the study. The study included 89 people suffering from the disease without symptoms. The study was conducted on 89 people suffering from the disease without symptoms, as half of them received 14 milligrams daily, while the other half obtained an imaginary agent, and they were followed up to two years. During the study, symptoms of “multiple sclerosis” appeared on 8 people who took the medicine, compared to 20 people who took the placebo. After adjusting other factors that may affect the risk of symptoms, researchers found that people taking the ‘turvonomic’ are 72 % less risk in light of the first symptoms of those taking the placebo. The results of the researchers indicate that early interference with “turvonomaide” can be useful for those diagnosed with multiple sclerosis without the occurrence of symptoms, that is, the previous stage of symptoms of “multiple nerve sclerosis”. However, more research in larger groups of people is needed to confirm the results of the researchers. Also read: